Pharmaids Pharmaceuticals Management

Management criteria checks 0/4

Pharmaids Pharmaceuticals' CEO is Prasad S., appointed in Jan 2024, has a tenure of less than a year. directly owns 1.21% of the company’s shares, worth ₹20.74M. The average tenure of the management team and the board of directors is 1.8 years and 1.8 years respectively.

Key information

Prasad S.

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	1.2%
Management average tenure	1.8yrs
Board average tenure	1.8yrs

Recent management updates

Recent updates

CEO

Prasad S. (47 yo)

less than a year

Tenure

Dr. Prasad S. was the Group Chief of Strategy and Operational Excellence at Pharmaids Pharmaceuticals Limited and serves as its Chief Executive Officer since January 6, 2024. He has extensive expertise in...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
B.C Balagangadhara	Chief Financial Officer	1.8yrs	₹1.87m	1.84% ₹ 31.3m
Kaushik Kumar	Company Secretary	1.8yrs	₹854.84k	no data
Venu Kaparthy	Executive Director	2.2yrs	₹2.70m	2.48% ₹ 42.2m
Mini Manikantan	Executive Director	2yrs	₹1.67m	1.42% ₹ 24.1m
Prasad S.	Chief Executive Officer	less than a year	no data	1.21% ₹ 20.5m
R. Bhavani	Accounts Officer	no data	no data	no data
Ingreed Anisha	Assistant Manager of Admin & Purchase	no data	no data	no data

1.8yrs

Average Tenure

43.5yo

Average Age

Experienced Management: 524572's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Venu Kaparthy	Executive Director	2.2yrs	₹2.70m	2.48% ₹ 42.2m
Mini Manikantan	Executive Director	2yrs	₹1.67m	1.42% ₹ 24.1m
Pattadamai Vijay	Independent Director	1.8yrs	₹209.00k	no data
Mopperthy Anand	Non-Executive Independent Director	18.3yrs	no data	no data
Shankarappa Nagaraj Babu	Non Executive Non Independent Chairman of the Board	less than a year	no data	14.74% ₹ 250.2m
Methuku Nagesh	Independent Non-Executive Director	1.7yrs	₹169.00k	no data
Shreedhara Shetty	Non-Executive & Non-Independent Director	less than a year	no data	18.7% ₹ 317.3m

1.8yrs

Average Tenure

55yo

Average Age

Experienced Board: 524572's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.

Pharmaids Pharmaceuticals Management

Management criteria checks 0/4

Key information

Recent management updates

Insider recently sold ₹1.1m worth of stock

Key Executive recently bought ₹1.1m worth of stock

Pharmaids Pharmaceuticals Limited Appoints Shankarappa Nagaraja Vinaya Babu as Non-Executive Non-Independent Director and Chairman

Insider recently sold ₹177k worth of stock

Pharmaids Pharmaceuticals Limited, Annual General Meeting, Sep 22, 2023

Pharmaids Pharmaceuticals Limited Announces Vyasmurti Madhavrao Shingatgeri Resigned from the Post of Independent Director of the Company

Recent updates

Insider recently sold ₹1.1m worth of stock

New major risk - Financial position

Pharmaids Pharmaceuticals Limited to Report Q4, 2024 Results on May 28, 2024

Key Executive recently bought ₹1.1m worth of stock

Pharmaids Pharmaceuticals Limited announced that it has received INR 525.448343 million in funding from Asian Hotels (North) Limited, Tumkur Trade Center Private Limited and another investors

Pharmaids Pharmaceuticals Limited Appoints Shankarappa Nagaraja Vinaya Babu as Non-Executive Non-Independent Director and Chairman

New minor risk - Share price stability

Pharmaids Pharmaceuticals Limited (BSE:524572) agreed to acquire 99.94% stake in Adita Bio Sys Private Ltd. for INR 530 million.

Pharmaids Pharmaceuticals Limited (BSE:524572) agreed to acquire 99.94% stake in Adita Bio Sys Private Ltd. for INR 530 million.

Insider recently sold ₹177k worth of stock

New major risk - Market cap size

New major risk - Financial position

Pharmaids Pharmaceuticals Limited to Report Q2, 2024 Results on Nov 11, 2023

United Biotech Private Limited Files Petition Against Pharmaids Pharmaceuticals Limited

United Biotech Private Limited Files Petition Against Pharmaids Pharmaceuticals Limited

Pharmaids Pharmaceuticals Limited, Annual General Meeting, Sep 22, 2023

Pharmaids Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Aug 29, 2023

New major risk - Market cap size

Pharmaids Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 04, 2023

Pharmaids Pharmaceuticals Limited to Report Q4, 2023 Results on May 29, 2023

Third quarter 2023 earnings released: ₹0.54 loss per share (vs ₹0.013 profit in 3Q 2022)

Pharmaids Pharmaceuticals Limited to Report Q3, 2023 Results on Feb 13, 2023

Pharmaids Pharmaceuticals Limited Announces Vyasmurti Madhavrao Shingatgeri Resigned from the Post of Independent Director of the Company

Pharmaids Pharmaceuticals Approves Appointment of Pattamadai Natarajasarma Vijay as an Independent Director

High number of new and inexperienced directors

Pharmaids Pharmaceuticals Limited announced that it expects to receive INR 168 million in funding

Pharmaids Pharmaceuticals Limited Approves Resignation of Veerareddy Vallapureddy as Independent Director

High number of new and inexperienced directors

Pharmaids Pharmaceuticals Limited to Report Q2, 2023 Results on Nov 09, 2022

High number of new and inexperienced directors

Pharmaids Pharmaceuticals Limited Announces Change of Company Secretary and Compliance Officer

Pharmaids Pharmaceuticals Limited Informes Vyasmurti Madhavrao Shingatgeri Resigns from the Post of Independent Director

Pharmaids Pharmaceuticals Limited, Annual General Meeting, Aug 20, 2022

Pharmaids Pharmaceuticals Limited, Annual General Meeting, Aug 20, 2022

Pharmaids Pharmaceuticals Limited to Report Q1, 2023 Results on Jul 22, 2022

Pharmaids Pharmaceuticals Limited Announces Resignation of Viswa Prasad Sadhanala as Whole Time Director

High number of new and inexperienced directors

Pharmaids Pharmaceuticals Limited Announces Executive Changes

Pharmaids Pharmaceuticals Limited to Report Q4, 2022 Results on May 21, 2022

High number of new and inexperienced directors

Board Member recently sold ₹5.5m worth of stock

Board Member recently sold ₹3.2m worth of stock

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Board Member recently sold ₹5.9m worth of stock

Second quarter 2022 earnings released: EPS ₹0.07 (vs ₹0.04 in 2Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Pharmaids Pharmaceuticals Limited to Report Q3, 2021 Results on Feb 05, 2021

Pharmaids Pharmaceuticals Limited Announces Board Appointments

New 90-day high: ₹18.02

Pharmaids Pharmaceuticals Limited Announces Resignation of Dasi Reddy Rakesh as Executive Director

New 90-day high: ₹8.68

Pharmaids Pharmaceuticals Limited to Report First Half, 2021 Results on Nov 12, 2020

Pharmaids Pharmaceuticals Limited (BSE:524572) completed the acquisition of Emergent Bio Naturals Limited.

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age